Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration

Mar 14 2024

• By Joseph Haas and Mary Jo Laffler

Liver disease

Related Content

Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT

Jul 23 2020

Intercept, Madrigal Get Ready For NASH Commercialization

Mar 02 2023

AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

Nov 17 2023

Novo Nordisk Has Plans For Semaglutide In NASH Too

Nov 15 2023

Madrigal Shows Confidence As It Awaits FDA’s March Decision On Resmetirom

Nov 13 2023

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Nov 29 2023

ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access

May 26 2023

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

Sep 26 2023

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

Sep 22 2023

Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

Jun 23 2023

Akero’s 96-Week Fibrosis Data Sparkle In MASH

Mar 05 2024

Madrigal Phase III Success In NASH Spurs Buyout Speculation

Dec 19 2022

Related Companies

Madrigal Pharmaceuticals, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Viking Therapeutics, Inc.

Novo Nordisk A/S

Inventiva S.A.

Akero Therapeutics, Inc.

89bio, Inc.

Additional Topics

Approvals Launches Commercial Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window